A new oral medication called VDPHL01 has passed a critical phase II/III clinical trial, showing nearly 80% of participants experienced noticeable hair coverage improvement, marking a potential breakthrough for treating pattern hair loss.
- Nearly 80% of men saw hair growth improvements with VDPHL01.
- The drug is generally well tolerated, with side effects similar to placebo.
- Results pave the way for potential FDA approval in 2026.
What happened
In a recent phase II/III clinical trial involving 519 men, VDPHL01, an oral minoxidil formulation designed for pattern hair loss, demonstrated remarkable results. Participants taking one or two doses daily reported significant improvements in hair coverage compared to those on placebo. The higher dose group saw an average hair growth increase of 33 hairs per square centimeter over six months, compared to only 7.3 hairs in the placebo group.
The trial also highlighted the medication’s safety profile, as participants tolerated it well. The rate at which participants discontinued the drug was comparable to those taking the placebo, indicating minimal adverse effects. These positive outcomes position VDPHL01 as a potential first new effective oral treatment for pattern hair loss in nearly 30 years.
Why it feels good
Pattern hair loss is a widespread concern, affecting approximately 80 million adults in the United States alone. The arrival of an effective, non-hormonal oral therapy like VDPHL01 could greatly expand treatment options beyond topical or hormonal solutions, which often come with limitations or side effects.
Experts see promise in VDPHL01’s ability to fit into dermatologists’ current prescribing practices since it is based on minoxidil, a well-known hair growth agent. Its extended-release formulation improves efficacy while minimizing the risk of cardiac side effects, offering a welcomed alternative that aligns with patient needs and comfort.
What to enjoy or watch next
In parallel, Veradermics has initiated a dedicated Phase II/III study for female pattern hair loss, known as Study 306. This means both men and women may soon have access to a new oral treatment that could transform how hair loss is managed globally.